Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 4, 2011, Pages 366-373

  Nardi, A E ^a   Valenca A M ^a,b   Freire, R C ^a   Mochcovitch, M D ^a   Amrein, R ^a   Sardinha, A ^a   Levitan, M N ^a   Nascimento, I ^a   de Melo Neto, V L ^a,c   King, A L ^a   e Silva, A C de O ^a,b   Veras, A B ^a   Dias, G P ^a   Soares Filho, G L ^a,d   da Costa, R T ^a   Mezzasalma, M A ^a   de Carvalho, M R ^a   de Cerqueira, A C ^a   Hallak, J E ^e   Crippa, J A ^e   Versiani, M ^a   more..

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Universidade Federal Fluminense   (Brazil)

^c Faculdade de Medicina da Universidade Federal de Alagoas   (Brazil)

^d HOSPITAL PRÓ CARDÍACO   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Clonazepam; Efficacy; Panic disorder; Paroxetine; Safety

Indexed keywords

CLONAZEPAM; PAROXETINE;

AGORAPHOBIA; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NAUSEA AND VOMITING; PANIC; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TASTE DISCRIMINATION; TREMOR; WEAKNESS; WEIGHT CHANGE; XEROSTOMIA;

EID: 79955379856     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500020     Document Type: Article

References (40)

1. Bienvenu OJ. Lifetime prevalence of panic disorder is about 5% in the USA. Evid Based Ment Health 2006; 9: 114.
2. Hirschfeld RM. Panic disorder: diagnosis, epidemiology, and clinical course. J Clin Psychiatry 1996; 57 (Suppl 10): 3-8.
3. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000; 157: 669-682.
4. Mogotsi M, Kaminer D, Stein DJ. Quality of life in the anxiety disorders. Harv Rev Psychiatry 2000; 8: 273-282.
5. Waghorn G, Chant D, White P, Whiteford H. Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust N Z J Psychiatry 2005; 39: 55-66.
6. Marchesi C. Pharmacological management of panic disorder. Neuropsychiatr Dis Treat 2008; 4: 93-106.
7. Mitte K. A meta-analysis of the efficacy of psycho-and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005; 88: 27-45.
8. Pull CB, Damsa C. Pharmacotherapy of panic disorder. Neuropsychiatr Dis Treat 2008; 4: 779-795.
9. Bandelow B, Ruther E. Treatment-resistant panic disorder. CNS Spectr 2004; 9: 725-739.
10. Nardi AE, Nascimento I, Valenca AM, Lopes FL, Mezzasalma MA, Zin WA, et al. Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricyclic antidepressant. Psychiatry Res 2003; 120: 283-293.
11. Nardi AE, Valenca AM, Nascimento I, Lopes FL, Mezzasalma MA, Freire RC, et al. A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam. Psychiatry Res 2005; 137: 61-70.
12. Valenca AM, Nardi AE, Mezzasalma MA, Nascimento I, Zin WA, Lopes FL, et al. Therapeutic response to benzodiazepine in panic disorder subtypes. São Paulo Med J 2003; 121: 77-80.
13. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 2004; 65: 1696-1707.
14. Susman J, Klee B. The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiatry 2005; 7: 5-11.
15. Bakker A, van Balkom AJ, van Dyck R. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol 2000; 15 (Suppl 2): S25-S30.
16. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry 1998; 155: 1-34.
17. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry 2004; 4: 16.
18. Pollack MH, Doyle AC. Treatment of panic disorder: focus on paroxetine. Psychopharmacol Bull 2003; 37 (Suppl 1): 53-63.
19. Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005; 66: 34-40.
20. Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003; 160: 1432-1438.
21. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 1997; 17: 390-400.
22. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004; 65 (Suppl 5): 7-12.
23. Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol 1986; 43: 629-643.
24. Moroz G. High-potency benzodiazepines: recent clinical results. J Clin Psychiatry 2004; 65 (Suppl 5): 13-18.
25. Nardi AE, Perna G. Clonazepam in the treatment of psychiatric disorders: an update. Int Clin Psychopharmacol 2006; 21: 131-142.
26. Zamorski MA, Albucher RC. What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder. Am Fam Physician 2002; 66: 1477-1484.
27. Nardi AE, Valença AM, Freire RC, Amrein R, Sardinha A, Levitan MN, et al. Randomized open naturalistic acute treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol 2011 (in press).
28. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a doubleblind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994; 14: 111-118.
29. Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebocontrolled, multicenter study using optimized dosages. J Clin Psychiatry 1999; 60: 604-612.
30. Valenca AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, Zin W. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr 2000; 58: 1025-1029.
31. Dannon PN, Iancu I, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Clonazepam augmentation of paroxetine in the treatment of panic disorder: a one year naturalistic followup study. Internet J Ment Health 2005; http://www.ispub.com/journal/the_internet_journal_of_mental_health/archive/volume_2_number_2_31.html (Accessed: January 5, 2011).
32. Dannon PN, Lowengrub K, Iancu I, Kotler M. Paroxetine in panic disorder: clinical management and long-term followup. Expert Rev Neurother 2004; 4: 191-198.
33. American Psychiatric Association. Practice guidelines for the treatment of psychiatric disorders compendium. Arlington: American Psychiatric Press; 2004.
34. Saeki Y, Watanabe T, Ueda M, Saito A, Akiyama K, Inoue Y, et al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol 2009; 65: 685-691.
35. Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl 1991; 365: 18-27.
36. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003; 17: 276-282.
37. Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, et al. Paroxetine: safety and tolerability issues. Expert Opin Drug Saf 2008; 7: 783-794.
38. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999; 7: 69-84.
39. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998; 18: 12S-18S.
40. Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J Psychiatr Res 1993; 27 (Suppl 1): 97-110.